Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response

Open Access

2 June 2005

journal article
research article
Published by Elsevier in Annals of Oncology

Vol. 16 (7) , 995-996
https://doi.org/10.1093/annonc/mdi230

Abstract

The article by Lassau et al. [1] on the use of contrast-enhanced Doppler ultrasound (Doppler US) for early and rapid assessment of tumour response after isolated limb perfusion (ILP) for locally advanced soft tissue sarcomas (STSs) of the extremities is an excellent example of the new opportunities that arise with rapidly evolving technologies in imaging. In the quest for early predictors and surrogate markers for response this technology represents a relatively simple, practical and cheap procedure.

Keywords

This publication has 10 references indexed in Scilit:

Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases
Annals of Oncology, 2005
Molecular Imaging of Antiangiogenic Agents
The Oncologist, 2005
Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas
Magnetic Resonance Materials in Physics, Biology and Medicine, 2004
³¹Phosphorus‐magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors
Cancer, 2002
FDG Positron Emission Tomography in Isolated Limb Perfusion Therapy in Patients with Locally Advanced Melanoma
Clinical Nuclear Medicine, 2001
Dynamic Contrast-enhanced MRI Studies in Oncology with an Emphasis on Quantification, Validation and Human Studies
Clinical Radiology, 2001
Evaluation of Contrast-Enhanced Color Doppler Ultrasound for the Quantification of Angiogenesis In Vivo
Investigative Radiology, 2001
In vivo monitoring of tumor angiogenesis with MR imaging
Academic Radiology, 2000
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Journal of Clinical Oncology, 1996